CN103142657A - Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia - Google Patents
Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia Download PDFInfo
- Publication number
- CN103142657A CN103142657A CN2013100857138A CN201310085713A CN103142657A CN 103142657 A CN103142657 A CN 103142657A CN 2013100857138 A CN2013100857138 A CN 2013100857138A CN 201310085713 A CN201310085713 A CN 201310085713A CN 103142657 A CN103142657 A CN 103142657A
- Authority
- CN
- China
- Prior art keywords
- bacteroides fragilis
- application
- compositions
- preventing
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000606124 Bacteroides fragilis Species 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 14
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000021107 fermented food Nutrition 0.000 claims description 2
- -1 granular preparation Substances 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 238000002474 experimental method Methods 0.000 abstract description 8
- 239000006041 probiotic Substances 0.000 abstract description 7
- 230000000529 probiotic effect Effects 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 9
- 238000003304 gavage Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 244000005700 microbiome Species 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- UIMGHSAOLFTOBF-DPAQBDIFSA-N 3beta-Hydroxycholest-4-ene Chemical class C1CC2=C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 UIMGHSAOLFTOBF-DPAQBDIFSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating hypercholesteremia. Experiments show that bacteroides fragilis is safe, nontoxic and strong in pharmacologic action and has good preventing and treating effect to hypercholesteremia, thereby indicating that the bacteroides fragilis has good edible and officinal prospects. The invention explores novel use of bacteroides fragilis and develops a novel application field. Bacteroides fragilis as probiotic can be used for preparing foods or medical compositions for preventing and treating hypercholesteremia so as to provide a clinically health-care and preventing and treating food suitable for human to take.
Description
Technical field
The present invention relates to the applied technical field of bacteroides fragilis, be specifically related to bacteroides fragilis and prevent and treat the application in the hypercholesterolemia compositions in preparation.
Background technology
Hypercholesterolemia is one of main hazard factor caused atherosclerosis and related cardiovascular disease (for example coronary heart disease), how to reduce serum cholesterol and has become the topic that modern nutriology man and clinician more and more are concerned about.Hypercholesterolemia, without obvious clinical symptoms, is often found when health check-up.Current prophylactico-therapeutic measures mainly comprises behavior control and Drug therapy.In recent decades, the risk that cardiovascular disease occurs the crowd who it is found that the long-term drink Yoghourt obviously reduces, and a large amount of scientific researches confirm that this is relevant with probiotic bacteria contained in Yoghourt.
In probiotic bacteria, humans and animals there is the bacterial strain of fine effect after absorption by the bacillus bifidus of extensive concern and lactobacillus, their specific bacterial strain can be settled down on intestinal mucosa, the built-in group of intestinal and prevent that harmful microorganism from adhering to thereon, be to promote the microorganism formulation of growing of bion health by keeping enteral natural microorganisms fauna, help maintains the health of humans and animals.The microbial ecological agent of bacillus bifidus, lactobacillus, can make cholesterol be converted into the non-absorbent coprostenol class of human body material after clothes, thereby reduce cholesterol levels.
Bacteroides fragilis (
bacteroides fragilis) as a kind of Gram-negative, shaft-like, blunt round and dense the dying in two ends, pod membrane is arranged, without brood cell, motorless obligate anaerobes, minute produce enterotoxin type and non-product enterotoxin type.Bacteroides fragilis, as the part of people and animal intestinal normal flora, mainly is stored in colon, in addition, but the also field planting growth of respiratory tract, gastrointestinal tract and urogenital tract mucosa.What research was more at present is that bacteroides fragilis is as a kind of conditioned pathogen, when host's mucosa is impaired, can invade tela submucosa, cause infection, also can be through blood flow, cause that other organ of health is as intestinal, abdominal cavity, liver, lung, cerebral tissue pyogenic infection the abscess and cause acute and chronic diarrhea etc. of occurring together.In addition, its generation to colorectal cancer also has facilitation.
Yet bacteroides fragilis is not only a kind of conditioned pathogen.Within 1991, Zhang Jijie has delivered " isolation identification of a kind of nontoxic bacteroides fragilis ", reported about nineteen eighty-three JIUYUE separate the large and purer antibacterial of output from a well-developed infant faeces, warp is with serial evaluation, basic test and observation on Clinical Application, belong to a strain in the bacteroides fragilis group without toadstool, be the probiotic bacteria of human body, name the bacterial strain into BF839.Thus, study and found, bacteroides fragilis is also a kind of probiotic bacteria.But bacteroides fragilis is as a kind of probiotic bacteria, and prevent and treat the related application of hypercholesterolemia compositions in preparation, report is not yet arranged at present.
Summary of the invention
The object of the present invention is to provide bacteroides fragilis to prevent and treat the application in the hypercholesterolemia compositions in preparation.
In order to address the above problem, the technical solution adopted in the present invention is:
Provide bacteroides fragilis to prevent and treat the application in the hypercholesterolemia compositions in preparation, described bacteroides fragilis depositary institution name is called China Committee for Culture Collection of Microorganisms's common micro-organisms center, the depositary institution address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, preservation date is on March 12nd, 2013, deposit number is CGMCC No.7280, and Classification And Nomenclature is
Bacteroides fragilis.
Wherein, food or the pharmaceutical composition of described compositions at least containing the bacteroides fragilis that can prevent and treat hypercholesterolemia.
Wherein, described compositions is selected from any one in milk powder, cheese, curdled milk, Yoghourt, ice cream, milk base fermented food, fermented cereal food.
Wherein, described compositions is pill, tablet, granular preparation, capsule, oral liquid or tube feed preparation.
Wherein, described compositions is the liquid bacterial suspension that contains described bacteroides fragilis.
Wherein, the content of described bacteroides fragilis in described compositions is 10
8~ 10
10cfu/mL.
The invention has the beneficial effects as follows:
The present invention has excavated the new purposes of bacteroides fragilis, has opened up a new application.The present invention proves by experiment, the bacteroides fragilis safety non-toxic, and pharmacological action is strong, for hypercholesterolemia, good preventive and therapeutic action is arranged, thereby has indicated that bacteroides fragilis has well edible and prospect in medicine.Bacteroides fragilis, as a kind of probiotic bacteria, can be used for food or pharmaceutical composition that preparation prevents and treats hypercholesterolemia, for clinical providing is applicable to health care and the control non-defective unit that human body is taken.
the specific embodiment:
Below by embodiment, the present invention is described in further details, these embodiment only are used for illustrating the present invention, do not limit the scope of the invention.
the preparation of embodiment 1 bacteroides fragilis bacterium liquid
(1) separate bacteroides fragilis in infant faeces
Take 0.5 gram stool by " normal flora inspection technique ", be placed in the test tube that the 4.5ml normal saline first is housed, with this serial dilution, become 10
-1~ 10
-6, by the rare long-pending degree of height, to low rare long-pending degree, dripped on the Bd culture medium flat plate, be placed in the anaerobic gas generation box and add the anaerobic gas generation bag and carry out the anaerobism cultivation.Put 37 ℃, can opening inspection after 2 ~ 7 days.Choose single bacterium colony and carry out pure culture, dyeing microscopic examination, cultural character, Physiology and biochemistry detection.
(2) bacterium that increases of bacteroides fragilis is cultivated and bacterium solution preparation
Choose single colony inoculation after purification is increased bacterium and is cultivated in the tryptone meat soup of improvement, the centrifugation of gained bacterium liquid, rotating speed 3000r/min, centrifugal 15min, remove supernatant, after precipitate washs with normal saline, the precipitate normal saline dilution, do the bacterium number with the Maxwell opacity tube and measure, be diluted to 10
8cfu/ml, 10
9cfu/ml, 10
10cfu/ml, save backup.
embodiment 2 bacteroides fragilis virulence experiments
Adopt the bacteroides fragilis bacterium liquid of embodiment 1 preparation to carry out following experiment:
(1) chmice acute virulence experiment
Get 60 of body weight 22 ± 2 gram C57BR/C mices (male and female half and half), be divided into high dose group, low dose group and matched group, each organizes 20.Every mice gavage every day 10 of high dose group
12cfu/ml bacterium liquid 0.5ml, low dose group gavage every day 10
9cfu/ml bacterium liquid 0.5ml, matched group gavage every day 0.5ml normal saline.Continuous Observation 14 days.
Experimental result: the mice normal growth, have no dead, LD50 does not measure.
(2) rat virulence experiment
Get 30 of 150 ± 20 gram SD rats (male and female half and half), be divided into 3 groups: high low dose group and matched group.Every rat gavage every day 10 of high dose group
12cfu/ml bacterium liquid 2ml, low dose group gavage every day 10
9cfu/ml bacterium liquid 2ml, matched group gavage every day 2ml normal saline.Continuous Observation 14 days, phlebotomize after 14 days and survey hemogram, Liver and kidney merit.Get gastrointestinal liver spleen tissue and do the pathological section electron microscopic observation.
Experimental result: be showed no obvious abnormalities.
(3) Rhesus Macacus virulence experiment
Get 10 of Rhesus Macacus (male and female half and half), be divided into 2 groups: high low dose group and matched group.Every of high dose group Rhesus Macacus every day oral 10
12cfu/ml bacterium liquid 100ml, low dose group every day oral 10
9cfu/ml bacterium liquid 100ml.Continuous Observation 60 days.Phlebotomize respectively after 14 days, 30 days, 45 days, 60 days and survey hemogram, Liver and kidney merit, thought-read electrograph.Get gastrointestinal liver spleen tissue and do the pathological section electron microscopic observation.
Experimental result: be showed no obvious abnormalities.
embodiment 3 bacteroides fragiliss are for the preventive and therapeutic effect of hypercholesterolemia
Adopt the bacteroides fragilis bacterium liquid of embodiment 1 preparation to carry out following experiment:
Get the SD rat, body weight 200 ± 20 grams, after conforming one week, the tail venous blood sampling, measure blood lipid level, and blood fat is rejected by abnormal rat.At random the SD rat is divided into to 3 groups: normal group, high fat group, treatment group, 10 every group.Normal group gives normal feedstuff (protein 14%, fat 10%, carbohydrate 76%); High fat group and treatment group give high lipid food (having added 2% cholesterol, 1% cholic acid, 5% Oleum Arachidis hypogaeae semen); Treatment group gavage every day 2ml 10
9the bacteroides fragilis suspension of cfu/ml.
After 8 weeks, overnight fasting, after etherization, heart extracting blood is measured serum total cholesterol, triglyceride, HDL-C, low-density lipoprotein cholesterol.Get aorta, the heart, liver, kidney and do pathological section.
Experimental result: treatment group is compared high fat group serum total cholesterol and is obviously reduced, pathological section compared with normal group is without obvious change, and high fat group aorta slice arrives edema pathological change under local endo cell contraction and inner membrance, accidental Adherence of Monocytes is on inner membrance, and under inner membrance, accidental a small amount of foam cell is invaded profit.
Experimental result shows, the bacteroides fragilis of separation has good preventive and therapeutic effect for hypercholesterolemia, for atherosclerotic formation, good preventive and therapeutic action is also arranged.
Claims (6)
1. bacteroides fragilis prevents and treats the application in the hypercholesterolemia compositions in preparation.
2. the application of bacteroides fragilis according to claim 1 in preparation treatment inflammatory bowel compositions, is characterized in that: food or the pharmaceutical composition of described compositions at least containing the bacteroides fragilis that can prevent and treat hypercholesterolemia.
3. the application of bacteroides fragilis according to claim 2 in preparation treatment inflammatory bowel compositions, it is characterized in that: described compositions is selected from any one in milk powder, cheese, curdled milk, Yoghourt, ice cream, milk base fermented food, fermented cereal food.
4. the application of bacteroides fragilis according to claim 2 in preparation treatment inflammatory bowel compositions, it is characterized in that: described compositions is pill, tablet, granular preparation, capsule, oral liquid or tube feed preparation.
5. the application of bacteroides fragilis according to claim 1 in preparation treatment inflammatory bowel compositions, it is characterized in that: described compositions is the liquid bacterial suspension that contains described bacteroides fragilis.
6. the application of bacteroides fragilis according to claim 1 in preparation treatment inflammatory bowel compositions, it is characterized in that: the content of described bacteroides fragilis in described compositions is 10
8~ 10
10cfu/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100857138A CN103142657A (en) | 2013-03-18 | 2013-03-18 | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100857138A CN103142657A (en) | 2013-03-18 | 2013-03-18 | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103142657A true CN103142657A (en) | 2013-06-12 |
Family
ID=48541166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100857138A Pending CN103142657A (en) | 2013-03-18 | 2013-03-18 | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142657A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019047440A1 (en) * | 2017-09-11 | 2019-03-14 | 广州知易生物科技有限公司 | Application of bacteroides fragilis extract in preparing drug or food for preventing or treating inflammatory bowel disease |
| CN112138029A (en) * | 2020-10-31 | 2020-12-29 | 中国药科大学 | A kind of purposes of bacteroides ovatus for preparing anti-renal fibrosis medicine |
| CN112294851A (en) * | 2020-12-01 | 2021-02-02 | 中国药科大学 | A kind of purposes of Bacteroides fragilis for preparing anti-renal fibrosis medicine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056314A (en) * | 1990-05-03 | 1991-11-20 | 张李阶 | Useful bacterial strain of one strain and application thereof |
-
2013
- 2013-03-18 CN CN2013100857138A patent/CN103142657A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056314A (en) * | 1990-05-03 | 1991-11-20 | 张李阶 | Useful bacterial strain of one strain and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| JTT0213: "图腾益生菌", 《HTTP://BAIKE.BAIDU.COM/HISTORY/ID=10309074》, 7 February 2010 (2010-02-07) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019047440A1 (en) * | 2017-09-11 | 2019-03-14 | 广州知易生物科技有限公司 | Application of bacteroides fragilis extract in preparing drug or food for preventing or treating inflammatory bowel disease |
| CN112138029A (en) * | 2020-10-31 | 2020-12-29 | 中国药科大学 | A kind of purposes of bacteroides ovatus for preparing anti-renal fibrosis medicine |
| CN112294851A (en) * | 2020-12-01 | 2021-02-02 | 中国药科大学 | A kind of purposes of Bacteroides fragilis for preparing anti-renal fibrosis medicine |
| CN112294851B (en) * | 2020-12-01 | 2023-01-17 | 中国药科大学 | A kind of Bacteroides fragilis is used for the purposes of preparing anti-renal fibrosis medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108004189A (en) | A kind of compound probiotic lactic acid bacteria powder and preparation method and application | |
| CN103142656A (en) | Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer | |
| CN103156888A (en) | Application of bacteroides fragilis in preparation of composition for treating inflammatory bowel diseases | |
| CN109182207B (en) | Lactobacillus acidophilus La-SJLH001 with probiotic functions of regulating blood sugar level, cholesterol level and the like and application thereof | |
| CN111254090B (en) | Lactobacillus reuteri with weight losing function and application thereof | |
| CN103146620A (en) | Bacteroides fragilis with characteristics of probiotics | |
| GB2509475A (en) | Lactobacilus rhamnosus capable of relieving alcoholic chronic liver injury and application thereof | |
| CN109810912A (en) | One lactobacillus plantarum LH-511 and its application | |
| CN102112140A (en) | Effects of probiotics on humans and animals under environmental or biological changes | |
| CN110521785A (en) | Probiotics fermention functional food and its preparation | |
| CN107287133A (en) | One lactobacillus plantarum LLY 606 and its application | |
| CN110317761A (en) | A kind of bifidobacterium lactis and its application | |
| CN106883995A (en) | Pediococcus acidilactici JQII-5 bacterial strains and application thereof | |
| CN116746683B (en) | Animal Bifidobacterium lactis subspecies BAL-28 and its fermentation products, flora CW and application for preventing indigestion and flatulence and promoting absorption | |
| CN107227275A (en) | A kind of lactobacillus fermenti HY01 and application thereof | |
| CN109810913A (en) | One plant of Lactobacillus rhamnosus ASD-9 and its application | |
| CN105831534A (en) | Compound lactic acid bacteria beverage and a preparation method thereof | |
| CN106883997A (en) | Pediococcus pentosaceus JQI-7 bacterial strains and its application | |
| CN106962937A (en) | Prepare fermentation composition and preparation method with prevention conditioning hypertension, high fat of blood, hyperglycaemia and routine servicing effect plant enzyme | |
| CN111543639A (en) | Food composition and pharmaceutical composition containing lactic acid bacteria strain for protecting liver | |
| CN103082294A (en) | Application of bacteroides fragilis in preparation of composition for treating diarrhea | |
| CN103142657A (en) | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia | |
| CN101849969A (en) | Application of butyric acid producing beneficial bacterium in preparing preparation for preventing and treating severe disease gut barrier injury and post-injury complication | |
| CN107586746A (en) | One plant of lactic acid bacteria with preventing and treating mastitis for milk cows effect and its application | |
| KR20130130253A (en) | Method for manufacturing lactic acid fermented paecilomyces japonica improving intestinal motility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130612 |